Accretion Pharmaceuticals Limited (NSE:ACCPL)

Market Cap	1.20B
Revenue (ttm)	826.43M +329.7%
Net Income	90.81M
EPS	9.82
Shares Out	11.12M
PE Ratio	10.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,800
Average Volume	47,340
Open	111.40
Previous Close	109.40
Day's Range	107.00 - 114.85
52-Week Range	53.80 - 114.85
Beta	n/a
RSI	73.08
Earnings Date	May 8, 2026

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 125
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACCPL

Financial Performance

In fiscal year 2025, Accretion Pharmaceuticals's revenue was 573.76 million, an increase of 329.70% compared to the previous year's 133.53 million. Earnings were 67.94 million, an increase of 355.08%.